Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford - Oxford Vaccine Group
Galit Alter, VP of Immunology Research, Moderna
Montserrat Arroyo, Deputy Director General for International Standards and Science, WOAH
Francesco Berlanda Scorza, Director GVGH, GSK Vaccines for Global Health (GVGH)
Cedric Bogaert, Chief Executive Officer, MYNEO NV
Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
Michael Caldwell, Assoc VP Vaccine Research & Education, Meharry Medical College
Miles Carroll, Head of High Consequence Emerging Viruses Group, Pandemic Sciences Institute, University of Oxford
Andrew Catchpole, CSO, hVIVO
Ajoy Chakrabarti, Portfolio And Platform Lead, The Bill & Melinda Gates Foundation
Roman Chicz, Global Head Of External Research And Development, Sanofi
Dennis Christensen, Head of Global R&D, Croda
Tim Cooke, CEO, Omniose
Chad Costley, Chief Executive Officer, BlueWillow Biologics, Inc.
Jakob Cramer, Head Of Clinical Development, CEPI
Helge Dorfmuller, Principal Investigator, University of Dundee
Mark Emalfarb, Chief Executive Officer, Dyadic International Inc
Aaron Esser-Kahn, Professor, University of Chicago
Katie Ewer, Senior Project Leader, GSK
Antonio Garcia Maldonado, Investment Professional, Strategic Investment Fund, Bill and Melinda Gates Foundation
Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Marion Gruber, Vice President of Public Health and Regulatory Affairs, IAVI
Andrea Guerra, Regional Clinical Director Vaccines - Europe, MSD
Bassam Hallis, Deputy Director, Research and Evaluation, UK Health Security Agency
Ali M Harandi, Lab Head, Dpt Of Microbiology And Immunology, University of Gothenburg
Mateusz Hasso-Agopsowicz, Technical Officer, World Health Organization
Mark Howarth, Sheild Chair of Pharmacology, University Of Cambridge
Hans Keirstead, Chief Executive Officer, AIVITA Biomedical, Inc.
Edward Kelley, Chief Global Health Officer, ApiJect
Jerome Kim, Director General, IVI
Alexandre Le Vert, Chief Executive Officer, Osivax
Geert Leroux Roels, Professor Emeritus, Gent University
Ofer Levy, Director, Precision Vaccines Program, Boston Children's Hospital
Lenny Moise, VP, Research, SeromYx
Hanna Nohynek, Chief Physician, National Institute for Health and Welfare
Ab Osterhaus, Director of Research Center For Emerging Infections and Zoonoses and Professor, University of Veterinary Medicine Hannover
Serge Pampfer, Chief Executive Officer, LoValtech
Francesco Pappalardo, Deputy Director, Department of Drug and Health Sciences, University of Catania
Robert Paris, VP, Therapeutic Area Head, Latent Viruses, Moderna
Shanti Pather, Senior Global Medical Affairs Director, Vaccines, BioNTech SE
Haiko Pillu, Director Operations CPU, SGS
Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen
Ruben Rizzi, SVP Global Regulatory Affairs, BioNTech SE
Cesar Sanz Rodriguez, Vice President, Medical Affairs - Europe, Middle East & Africa, Moderna
Jerald Sadoff, Chief Medical Officer, Centivax
Jeremy Salt, Chief Executive Officer, The Vaccine Group
Gautam Sanyal, Principal Consultant, Vaccine Analytics, LLC, USA
Matthew Snape, VP, Clinical Development, Paediatric and Maternal Vaccines & Visiting Professor, Department of Paediatrics, University of Oxford, Moderna
Walter Straus, Vice President, Clinical Safety & Risk Management, Moderna Therapeutics
Nigel Temperton, Professor, University of Kent
Joris Vandeputte, President, IABS
Carla Vinals, VP Head of Regulatory Strategy, Moderna
Daniel Wolfe, Branch Chief, BARDA CBRN Vaccines, Biomedical Advanced Research And Development Authority
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events